RT Journal Article SR Electronic T1 Determining the Origins of Repeat Trichomonas vaginalis Infections Using Clinical Versus Genotype-Informed Criteria JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2022.01.31.22268862 DO 10.1101/2022.01.31.22268862 A1 Larkin, Heather A1 Bradic, Martina A1 Schmidt, Norine A1 Martin, David H. A1 Carlton, Jane M. A1 Kissinger, Patricia J. YR 2022 UL http://medrxiv.org/content/early/2022/02/01/2022.01.31.22268862.abstract AB Background High rates of repeat infections post-treatment are reported in women infected with Trichomonas vaginalis (TV). Determining the origin of repeat infections is generally limited to clinical queries of adherence to treatment and sexual exposure. The purpose of this study was to add micro-satellite (MS) genotype data to classification criteria for origin of repeat TV infection, and examine if the addition of TV genotype changes classification as treatment failure, re-infection, or new infectionMethods Women were enrolled at clinics in Birmingham, AL; Jackson, MS; and New Orleans, LA as part of a randomized clinical trial comparing single-dose (2 g) and multi-dose (500 mg twice daily x 7 days) metronidazole (MTZ) treatment regimens. Participants provided vaginal swabs and completed a behavioral audio-computer assisted self-interview (ACASI). TV specimens were genotyped at 11 microsatellite (MS) loci. Women with repeat TV infections at TOC, were classified as treatment failure, re-infection or new infections using behavioral and genotype data; classifications were compared.Results Data were available for 45 women. Genotype concordance was defined as <4 MS loci different and genotype discordance was defined as ≥ 4 MS loci different. Clinical criteria vs. genotype-informed criteria classifications were treatment failure (66.7% vs 64.4%) re-infection (26.7% vs. 17.8%) and new infections (6.7% vs. 17.8%) respectively; Bowker’s test of symmetry had Χ2=16.00 p=0.0011, indicating differences in results.Conclusions The majority of women, using either criteria, were classified as treatment failure. Clinical assessment may overestimate reinfections and underestimate new infections. Patient counseling should be adapted accordingly.Summary To more precisely determine the origin of repeat Trichomonas vaginalis infection, we compared genotype microsatellite size polymorphism data to clinical criteria and found that clinical data overestimated reinfection and underestimated new infections. Patient counselling should consider new partners.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT01018095Clinical Protocols https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6279510/ Funding StatementThis work was supported by the National Institute of Allergy and Infectious Diseases at the National Institutes of Health R01AI097080.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study received ethics approval from the institutional review boards of Tulane University, Louisiana State University Health Sciences Center (LSUHSC), University of Alabama at Birmingham, University of Mississippi MedicalCenter,JeffersonCountyDepartmentofHealth, and the Mississippi State Department of Health.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors